× Sunshine Policies and Murky Shadows in Europe: Disclosure of Pharmaceutical Industry Payments to Health Professionals in Nine European Countries 

× High Stakes Require More Than Just Talk: What to Do About Corruption in Health Systems Comment on “We Need to Talk About Corruption in Health Systems”

× Opening the Policy Window to Mobilize Action Against Corruption in the Health Sector Comment on “We Need to Talk About Corruption in Health Systems”

× Characterizing the Validity and Real-World Utility of Health Technology Assessments in Healthcare: Future Directions Comment on “Problems and Promises of Health Technologies: The Role of Early Health Economic Modelling”

× Using Open Public Meetings and Elections to Promote Inward Transparency and Accountability: Lessons From Zambia

× How Can Reasoned Transparency Enhance Co-Creation in Healthcare and Remedy the Pitfalls of Digitization in Doctor-Patient Relationships?

× Challenges to Establish Effective Public-Private Partnerships to Address Malnutrition in All Its Forms

× Commercial Influence on Political Declarations: The Crucial Distinction Between Consultation and Negotiation and the Need for Transparency in Lobbying Comment on “Competing Frames in Global Health Governance: An Analysis of Stakeholder Influence on the Political Declaration on Non-communicable Diseases”

× Tip of the Iceberg? Country- and Company-Level Analysis of Drug Company Payments for Research and Development in Europe

× How Openness Serves Innovation in Healthcare? Comment on “What Managers Find Important for Implementation of Innovations in the Healthcare Sector – Practice Through Six Management Perspectives”

× Biopharmaceutical Financialization and Public Funding of Medical Countermeasures (MCMs) in Canada During the COVID-19 Pandemic

× Characteristics and Distribution of Scholarship Donations From Pharmaceutical Companies to Japanese Healthcare Institutions in 2017: A Cross-sectional Analysis